HEVA Business Partner - Rare Disease and Rare Blood Disorder PortfolioSanofi, Cambridge, Massachusetts, USACambridge, Massachusetts, United States
PB0195 - Efanesoctocog Alfa Versus Emicizumab in the Prophylactic Treatment of Adolescents and Adults with Severe Hemophilia A Without Inhibitors: A Matching-Adjusted Indirect Comparison
Sunday, June 25, 202318:30 – 19:30 ET
PB0201 - Efanesoctocog Alfa Versus Extended Half-Life Factor VIII Therapies for Prophylaxis in Adolescents and Adults with Severe Hemophilia A: A Matching-Adjusted Indirect Comparison and Meta-Analysis
PB0213 - Efanesoctocog alfa vs. Standard Half-Life (Octocog Alfa) FVIII Therapies for Prophylaxis in Adolescents and Adults with Severe Hemophilia A: A Matching-Adjusted Indirect Comparison and Meta-Analysis
